Skip to main content
Erschienen in: Supportive Care in Cancer 8/2016

05.05.2016 | Review Article

Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review

verfasst von: Ricardo Fernandes, Sasha Mazzarello, Brian Hutton, Risa Shorr, Habeeb Majeed, Mohammed FK Ibrahim, Carmel Jacobs, Michael Ong, Mark Clemons

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Taxane acute pain syndrome (TAPS) is characterized by myalgias and arthralgias starting 24–48 h after taxane-based chemotherapy and lasting for 5–7 days. Relatively little is known about its incidence and impact on quality of life.

Objectives

A systematic review was conducted evaluating the incidence of TAPS in breast cancer patients receiving taxane-based chemotherapy.

Methods

Embase, Cochrane, and Ovid MEDLINE were searched from 1947 to July 2015. Data was sought from randomized controlled trials (RCTs), prospective and retrospective observational studies. Two reviewers independently screened citations and full text articles. Outcomes of interest were the incidence of TAPS and its impact on quality of life.

Results

Of 980 citations identified, 51 relevant studies (27,007 patients) were included. Data came from RCTs (12,357 patients), retrospective (6566 patients) and prospective observational studies (6210 patients). Study sample sizes ranged from 14 to 4149 patients (median 152). Given the significance between study heterogeneity, a meta-analysis was not performed. The incidence of TAPS varied between taxanes: paclitaxel (median 13.1 %, range 0.9–86 %), docetaxel (median 10.5 %, range 3.6–70 %), and nab-paclitaxel (26 %, range 14–43 %). In the metastatic setting, median incidence was 30 % (range 5.4–73 %), compared with 11.3 % (range 0.9–86 %) in the adjuvant setting. Three out of eight studies assessing quality of life demonstrated pain interference with daily activities.

Conclusions

The incidence of TAPS varies between taxanes, regimens, and disease settings. In order to identify patients at the greatest risk of TAPS, and hence optimize its prevention and management, standardized methods of diagnosing and measuring TAPS are needed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Bahl A, Oudard S, Tombal B, Özgürog M, Lu HS, et al. (2013) Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 24:2402–2408CrossRefPubMedPubMedCentral Bahl A, Oudard S, Tombal B, Özgürog M, Lu HS, et al. (2013) Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 24:2402–2408CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Trudeau M, Sinclair SE, Clemons M, et al. (2005) Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review. Cancer Treat Rev 31(4):283–302CrossRefPubMed Trudeau M, Sinclair SE, Clemons M, et al. (2005) Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review. Cancer Treat Rev 31(4):283–302CrossRefPubMed
4.
Zurück zum Zitat Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472–1478CrossRefPubMedPubMedCentral Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472–1478CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Saibil S (2010) Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol 17(4):42–47CrossRefPubMedPubMedCentral Saibil S (2010) Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol 17(4):42–47CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Beusterien K, Grinspan J, Kuchuk I, Mazzarello S, Dent S, Gertler S, et al. (2014) Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. Oncologist 19(2):127–134CrossRefPubMedPubMedCentral Beusterien K, Grinspan J, Kuchuk I, Mazzarello S, Dent S, Gertler S, et al. (2014) Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. Oncologist 19(2):127–134CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Kuchuk I, Bouganim N, Beusterien K, et al. (2013) Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat 142(1):101–107CrossRefPubMed Kuchuk I, Bouganim N, Beusterien K, et al. (2013) Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat 142(1):101–107CrossRefPubMed
8.
Zurück zum Zitat Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, et al. (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27:3611–3619CrossRefPubMed Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, et al. (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27:3611–3619CrossRefPubMed
9.
Zurück zum Zitat Jones SE, Savin MA, Holmes FA, ‘shaughnessy JAO, Blum JL, Vukelja S, et al. (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381–5387CrossRefPubMed Jones SE, Savin MA, Holmes FA, ‘shaughnessy JAO, Blum JL, Vukelja S, et al. (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381–5387CrossRefPubMed
10.
Zurück zum Zitat Roché H, Fumoleau P, Spielmann M, Canon J-L, Delozier T, Serin D, et al. (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24:5664–5671CrossRefPubMed Roché H, Fumoleau P, Spielmann M, Canon J-L, Delozier T, Serin D, et al. (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24:5664–5671CrossRefPubMed
11.
Zurück zum Zitat Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla J-P, Weaver C, et al. (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302–2313CrossRefPubMed Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla J-P, Weaver C, et al. (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302–2313CrossRefPubMed
12.
Zurück zum Zitat Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, et al. (2002) Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58. Clin Breast Cancer 3(5):333–340CrossRefPubMed Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, et al. (2002) Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58. Clin Breast Cancer 3(5):333–340CrossRefPubMed
13.
Zurück zum Zitat Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, et al. (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23:3686–3696CrossRefPubMed Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, et al. (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23:3686–3696CrossRefPubMed
14.
Zurück zum Zitat Borghaei H (2015) Nivolumab versus docetaxel in advanced Nonsquamous non-small cell lung cancer. N Engl J Med 373(17):1627–1639CrossRefPubMed Borghaei H (2015) Nivolumab versus docetaxel in advanced Nonsquamous non-small cell lung cancer. N Engl J Med 373(17):1627–1639CrossRefPubMed
15.
Zurück zum Zitat Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N engl j med. Chinese Acad Med Sci Shanghai — all China Maharaj Nakorn Chiang N Engl J Med 361(10):947–957 Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N engl j med. Chinese Acad Med Sci Shanghai — all China Maharaj Nakorn Chiang N Engl J Med 361(10):947–957
16.
Zurück zum Zitat Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. (2004) Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512CrossRefPubMed Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. (2004) Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512CrossRefPubMed
17.
Zurück zum Zitat Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, et al. (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15(4):396–405CrossRefPubMed Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, et al. (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15(4):396–405CrossRefPubMed
18.
Zurück zum Zitat Jacobs C, Hutton B, Mazzarello S, Smith S, Joy A, Amir E, et al. (2015) Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy—a survey of health care providers and patients. Support Care Cancer 23(11):3269–3275CrossRefPubMed Jacobs C, Hutton B, Mazzarello S, Smith S, Joy A, Amir E, et al. (2015) Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy—a survey of health care providers and patients. Support Care Cancer 23(11):3269–3275CrossRefPubMed
19.
Zurück zum Zitat Chow E, Nguyen J, Zhang L, Tseng L-M, Hou M-F, Fairchild A, et al. (2012) International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases. Cancer 118(5):1457–1465CrossRefPubMed Chow E, Nguyen J, Zhang L, Tseng L-M, Hou M-F, Fairchild A, et al. (2012) International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases. Cancer 118(5):1457–1465CrossRefPubMed
20.
Zurück zum Zitat Cella D, Peterman A, Hudgens S, Webster K, Socinski MA (2003) Measuring the side effects of taxane therapy in oncology the functional assessment of cancer therapy–taxane (FACT-taxane). Cancer 98(4):822–831CrossRefPubMed Cella D, Peterman A, Hudgens S, Webster K, Socinski MA (2003) Measuring the side effects of taxane therapy in oncology the functional assessment of cancer therapy–taxane (FACT-taxane). Cancer 98(4):822–831CrossRefPubMed
21.
Zurück zum Zitat Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, et al. (2012) Further data supporting that the paclitaxel-associated acute pain syndrome is associated with the development of peripheral neuropathy: NCCTG trial N08C1 1. Hematol Oncol Dayt 18(20):5171–5178 Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, et al. (2012) Further data supporting that the paclitaxel-associated acute pain syndrome is associated with the development of peripheral neuropathy: NCCTG trial N08C1 1. Hematol Oncol Dayt 18(20):5171–5178
22.
Zurück zum Zitat Loprinzi CL, Maddocks-Christianson K, Wolf SL, Rao RD, Dyck PJB, Mantyh P, Dyck P (2007) The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 13(6):399–403CrossRefPubMed Loprinzi CL, Maddocks-Christianson K, Wolf SL, Rao RD, Dyck PJB, Mantyh P, Dyck P (2007) The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 13(6):399–403CrossRefPubMed
23.
Zurück zum Zitat New PZ, Jackson CE, Rinaldi D, et al. (1996) Peripheral neuropathy secondary to docetaxel. Neurology 46:108–111CrossRefPubMed New PZ, Jackson CE, Rinaldi D, et al. (1996) Peripheral neuropathy secondary to docetaxel. Neurology 46:108–111CrossRefPubMed
24.
Zurück zum Zitat Hilkens PH, Verweij J, Stoter G, et al. (1996) Peripheral neurotoxicity induced by docetaxel. Neurology 46:104–108CrossRefPubMed Hilkens PH, Verweij J, Stoter G, et al. (1996) Peripheral neurotoxicity induced by docetaxel. Neurology 46:104–108CrossRefPubMed
25.
Zurück zum Zitat Nguyen V, Lawrence H (2004) Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol 22(9):1767–1769CrossRefPubMed Nguyen V, Lawrence H (2004) Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol 22(9):1767–1769CrossRefPubMed
26.
Zurück zum Zitat Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH, Jatoi AMT (2003) Glutamine does not prevent paclitaxel-associated myalgias and arthralgiasas. J Support Oncol 1(4):274–278PubMed Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH, Jatoi AMT (2003) Glutamine does not prevent paclitaxel-associated myalgias and arthralgiasas. J Support Oncol 1(4):274–278PubMed
27.
Zurück zum Zitat Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, et al. (1999) Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17(10):3038–3047PubMed Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, et al. (1999) Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17(10):3038–3047PubMed
28.
Zurück zum Zitat Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber C, et al. (2014) NCCTG N08CA (alliance): the use of glutathione for prevention of paclitaxel/carboplatin induced peripheral neuropathy: a phase III randomized, double-blind placebo-controlled study and for the alliance for clinical trials in oncology. Cancer 120(12):1890–1897CrossRefPubMedPubMedCentral Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber C, et al. (2014) NCCTG N08CA (alliance): the use of glutathione for prevention of paclitaxel/carboplatin induced peripheral neuropathy: a phase III randomized, double-blind placebo-controlled study and for the alliance for clinical trials in oncology. Cancer 120(12):1890–1897CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Sampson M, McGowan J, Cogo E, Grimshaw J, Moher DLC (2009) An evidence-based practice guideline for the peer review of electronic search. J Clin Epidemiol 62(9):944–952CrossRefPubMed Sampson M, McGowan J, Cogo E, Grimshaw J, Moher DLC (2009) An evidence-based practice guideline for the peer review of electronic search. J Clin Epidemiol 62(9):944–952CrossRefPubMed
30.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269CrossRefPubMed Moher D, Liberati A, Tetzlaff J, et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269CrossRefPubMed
31.
Zurück zum Zitat Higgins Senior Statistician JPT, Altman Director DG, Gøtzsche Director PC, Jüni P. (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343(d5928). Higgins Senior Statistician JPT, Altman Director DG, Gøtzsche Director PC, Jüni P. (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343(d5928).
32.
Zurück zum Zitat Fountzilas G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki AG, et al. (2014) Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic cooperative oncology group randomized phase III trial. BMC Cancer 14:515CrossRefPubMedPubMedCentral Fountzilas G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki AG, et al. (2014) Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic cooperative oncology group randomized phase III trial. BMC Cancer 14:515CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, Kokko R, Asola R. (2009) Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T)– > 5FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): Interim analysis of the FinXX-trial. Cancer Res 69:2 Suppl S). Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, Kokko R, Asola R. (2009) Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T)– > 5FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): Interim analysis of the FinXX-trial. Cancer Res 69:2 Suppl S).
34.
Zurück zum Zitat Kim WY, Woo U, Seo JH, Son GS, Lee JB, Bae JW (2011) Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases. J Cancer Res Ther 7(4):412–415CrossRefPubMed Kim WY, Woo U, Seo JH, Son GS, Lee JB, Bae JW (2011) Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases. J Cancer Res Ther 7(4):412–415CrossRefPubMed
35.
Zurück zum Zitat Wist EA, Mjaaland I, Løkkevik E, Sommer HH (2012) Clinical study weekly paclitaxel plus capecitabine versus docetaxel every 3 weeks plus capecitabine in metastatic breast cancer. J Oncol Hindawi Publishing Corporation. doi:10.1155/2012/862921 Wist EA, Mjaaland I, Løkkevik E, Sommer HH (2012) Clinical study weekly paclitaxel plus capecitabine versus docetaxel every 3 weeks plus capecitabine in metastatic breast cancer. J Oncol Hindawi Publishing Corporation. doi:10.​1155/​2012/​862921
36.
Zurück zum Zitat Lin Y-C, Chang H-K, Chen J-S, Wang H-M, Yang T-S, Liaw C-C (2007) A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis. Jpn J Clin Oncol 37(1):23–29CrossRefPubMed Lin Y-C, Chang H-K, Chen J-S, Wang H-M, Yang T-S, Liaw C-C (2007) A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis. Jpn J Clin Oncol 37(1):23–29CrossRefPubMed
37.
Zurück zum Zitat Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, et al. (2014) Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol 25(3):592–598CrossRefPubMedPubMedCentral Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, et al. (2014) Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol 25(3):592–598CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Pasekta M, Giotis A (2011) Characterization of taxane-induced arthralgias and myalgias in breast cancer patients at two ambulatory cancer centres: a prospective observational study. Support Care Cancer 19(Suppl.1):S312 Pasekta M, Giotis A (2011) Characterization of taxane-induced arthralgias and myalgias in breast cancer patients at two ambulatory cancer centres: a prospective observational study. Support Care Cancer 19(Suppl.1):S312
39.
Zurück zum Zitat Howell SJ, Armstrong ACAL (2012) Retrospective analysis of the relative efficacy and toxicity of nab-paclitaxel and docetaxel in metastatic breast cancer. Eur J Cancer 48:S115–S116CrossRef Howell SJ, Armstrong ACAL (2012) Retrospective analysis of the relative efficacy and toxicity of nab-paclitaxel and docetaxel in metastatic breast cancer. Eur J Cancer 48:S115–S116CrossRef
40.
Zurück zum Zitat Brammer M, Lalla D, Guerin A, Yu A, Wu E (2011) Complications associated with chemotherapy in patients with metastatic breast cancer. Eur J Cancer 47:S330CrossRef Brammer M, Lalla D, Guerin A, Yu A, Wu E (2011) Complications associated with chemotherapy in patients with metastatic breast cancer. Eur J Cancer 47:S330CrossRef
41.
Zurück zum Zitat Coudert BP, Pierga J-Y, Mouret-Reynier M-A, Kerrou K, Ferrero J-M, Petit T et al. (2014) An open-label, randomized, multicenter study investigating the addition of bevacizumab to neoadjuvant trastuzumab plus docetaxel in patients with early stage HER2-positive breast cancer stratified according to PET change after one therapy cycle. J Clini Oncol 32(15(Suppl. 1)). Coudert BP, Pierga J-Y, Mouret-Reynier M-A, Kerrou K, Ferrero J-M, Petit T et al. (2014) An open-label, randomized, multicenter study investigating the addition of bevacizumab to neoadjuvant trastuzumab plus docetaxel in patients with early stage HER2-positive breast cancer stratified according to PET change after one therapy cycle. J Clini Oncol 32(15(Suppl. 1)).
42.
Zurück zum Zitat Moon YW, Lee S, Park B-W, Kim E-K, Kim SI, Koo JS, et al. (2013) S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. BMC Cancer 13:583CrossRefPubMedPubMedCentral Moon YW, Lee S, Park B-W, Kim E-K, Kim SI, Koo JS, et al. (2013) S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. BMC Cancer 13:583CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Malgorzata KT, Soeren C, Ulla BT, Soendergaard S, Nielsen D (2012) Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide+/−trastuzumab followed by docetaxel in locally advanced breast cancer. Eur J Cancer 48:S173 Malgorzata KT, Soeren C, Ulla BT, Soendergaard S, Nielsen D (2012) Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide+/−trastuzumab followed by docetaxel in locally advanced breast cancer. Eur J Cancer 48:S173
44.
Zurück zum Zitat Bulent AM, Algin E, Inal A, et al. (2013) Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study. J BUON 18(2):314–320 Bulent AM, Algin E, Inal A, et al. (2013) Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study. J BUON 18(2):314–320
45.
Zurück zum Zitat Hatam N, Ahmadloo N, Ahmad KDA, Daliri A, et al. (2011) Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil). Arch Gynecol Obstet 284(1):215–220CrossRefPubMed Hatam N, Ahmadloo N, Ahmad KDA, Daliri A, et al. (2011) Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil). Arch Gynecol Obstet 284(1):215–220CrossRefPubMed
46.
Zurück zum Zitat Eckhoff L, Nielsen M, Moeller S, Knoop A (2011) TAXTOX – a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol 50(7):1075–1082CrossRefPubMed Eckhoff L, Nielsen M, Moeller S, Knoop A (2011) TAXTOX – a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol 50(7):1075–1082CrossRefPubMed
47.
Zurück zum Zitat Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, et al. (2011) Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: BCIRG-005 Trial. J Clin Oncol 10;29(29):3877–84. Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, et al. (2011) Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: BCIRG-005 Trial. J Clin Oncol 10;29(29):3877–84.
48.
Zurück zum Zitat Miura D, Fujii M, Iwatani T, Takano T, Kawabata H. (2011) Reduction of toxicity by reversing the order of infusion in docetaxel and cyclophosphamide (TC). J Clin Oncol 29(15):Suppl 3. Miura D, Fujii M, Iwatani T, Takano T, Kawabata H. (2011) Reduction of toxicity by reversing the order of infusion in docetaxel and cyclophosphamide (TC). J Clin Oncol 29(15):Suppl 3.
49.
Zurück zum Zitat Schönherr A, Aivazova-Fuchs V, Annecke K, et al. (2012) Toxicity analysis in the ADEBAR trial: sequential anthracycline-taxane therapy compared with FEC120 for the adjuvant treatment of high-risk breast cancer. Breast Care 7:289–295CrossRefPubMedPubMedCentral Schönherr A, Aivazova-Fuchs V, Annecke K, et al. (2012) Toxicity analysis in the ADEBAR trial: sequential anthracycline-taxane therapy compared with FEC120 for the adjuvant treatment of high-risk breast cancer. Breast Care 7:289–295CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Boekel N, Schaapveld M, Aleman BMP, et al. (2010) Musculoskeletal pain in the FEC-D regimen is common and frequently severe—experiences in an outer metropolitan oncology unit. Eur J Cancer Suppl 8:163–164CrossRef Boekel N, Schaapveld M, Aleman BMP, et al. (2010) Musculoskeletal pain in the FEC-D regimen is common and frequently severe—experiences in an outer metropolitan oncology unit. Eur J Cancer Suppl 8:163–164CrossRef
51.
Zurück zum Zitat Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, et al. (2011) Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × docetaxel. BMC Cancer 11:140CrossRefPubMedPubMedCentral Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, et al. (2011) Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × docetaxel. BMC Cancer 11:140CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Yau TK, Sayeed A, Shen ZZ, Kim SB, Ali SM, Villalon AH, et al. (2010) Patterns of care and safety profiles of adjuvant docetaxel-based chemotherapy regimens in a large breast cancer registry study in Asia Pacific. Eur J Cancer Suppl 8(3):216CrossRef Yau TK, Sayeed A, Shen ZZ, Kim SB, Ali SM, Villalon AH, et al. (2010) Patterns of care and safety profiles of adjuvant docetaxel-based chemotherapy regimens in a large breast cancer registry study in Asia Pacific. Eur J Cancer Suppl 8(3):216CrossRef
53.
Zurück zum Zitat Rodriguez-Abreu D, Murias A, García M et al. (2009) Neoadjuvant biweekly dose-dense chemotherapy with fluouracil, epirubicin, and cyclophosphamide (FEC 90), followed by docetaxel in patients with HER2-neu negative primary breast cancer. J Clin Oncol 27(15s):suppl;abstr 596. Rodriguez-Abreu D, Murias A, García M et al. (2009) Neoadjuvant biweekly dose-dense chemotherapy with fluouracil, epirubicin, and cyclophosphamide (FEC 90), followed by docetaxel in patients with HER2-neu negative primary breast cancer. J Clin Oncol 27(15s):suppl;abstr 596.
54.
Zurück zum Zitat Lee KS, Ro J, Nam BH, et al. (2008) A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cnacer Res Treat 109(3):481–489CrossRef Lee KS, Ro J, Nam BH, et al. (2008) A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cnacer Res Treat 109(3):481–489CrossRef
55.
Zurück zum Zitat Vriens B, Smilde T, Van de Vjiver K. (2011) Sequential versus upfront intensified neoadjuvant chemotherapy in patients with large resectable or locally advanced breast cancer (INTENS), toxicity results from a phase III study of the dutch breast cancer triallists group (BOOG). Cancer Res 71(24):Suppl. 1. Vriens B, Smilde T, Van de Vjiver K. (2011) Sequential versus upfront intensified neoadjuvant chemotherapy in patients with large resectable or locally advanced breast cancer (INTENS), toxicity results from a phase III study of the dutch breast cancer triallists group (BOOG). Cancer Res 71(24):Suppl. 1.
56.
Zurück zum Zitat Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, et al. (2011) Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. J Clin Oncol 29(24):3247–3254CrossRefPubMed Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, et al. (2011) Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. J Clin Oncol 29(24):3247–3254CrossRefPubMed
57.
Zurück zum Zitat Jacot W, Bibeau F, Gourgou-Bourgade S, Gutowski M, Colombo P-E, Bleuse J-P, et al. (2010) Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer. Am J Clin Oncol 33:544–549CrossRefPubMed Jacot W, Bibeau F, Gourgou-Bourgade S, Gutowski M, Colombo P-E, Bleuse J-P, et al. (2010) Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer. Am J Clin Oncol 33:544–549CrossRefPubMed
58.
Zurück zum Zitat Morimoto M, Nakagawa M, Takechi H, Tadokoro YT (2014) A phase II study with S-1 + docetaxel (N-1 study) for advanced breast cancer. Eur J Cancer 50(S51) Morimoto M, Nakagawa M, Takechi H, Tadokoro YT (2014) A phase II study with S-1 + docetaxel (N-1 study) for advanced breast cancer. Eur J Cancer 50(S51)
59.
Zurück zum Zitat Swain S, Baselga J, Miles D, Knott A, Clark E, Ross G, et al. (2014) Safety profile of Pertuzumab with trastuzumab and docetaxel in patients from Asia with human epidermal growth factor receptor 2- positive metastatic breast cancer: results form the phase III trial CLEOPATRA. Oncologist 19:693–701CrossRefPubMedPubMedCentral Swain S, Baselga J, Miles D, Knott A, Clark E, Ross G, et al. (2014) Safety profile of Pertuzumab with trastuzumab and docetaxel in patients from Asia with human epidermal growth factor receptor 2- positive metastatic breast cancer: results form the phase III trial CLEOPATRA. Oncologist 19:693–701CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Earl H, Vallier A, Hiller L, Fenwick N, Young J, Iddawela M (2014) Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (neo-tAnGo): an open-label, 2 × 2 factorial randomised phase 3 trial. Lancet Oncol 15:201–212CrossRefPubMed Earl H, Vallier A, Hiller L, Fenwick N, Young J, Iddawela M (2014) Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (neo-tAnGo): an open-label, 2 × 2 factorial randomised phase 3 trial. Lancet Oncol 15:201–212CrossRefPubMed
61.
Zurück zum Zitat Gonzalez-Angulo A, Akcakanat A, Liu S, Green M, Murray J, Chen H (2014) Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol 25:1122–1127CrossRefPubMedPubMedCentral Gonzalez-Angulo A, Akcakanat A, Liu S, Green M, Murray J, Chen H (2014) Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol 25:1122–1127CrossRefPubMedPubMedCentral
62.
Zurück zum Zitat Saura C, Pusztain L (2013) Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel en early stage breast cancer and evaluation of BIII-tubulin expression as a predictive marker. Oncologist 18:787–794CrossRefPubMedPubMedCentral Saura C, Pusztain L (2013) Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel en early stage breast cancer and evaluation of BIII-tubulin expression as a predictive marker. Oncologist 18:787–794CrossRefPubMedPubMedCentral
63.
Zurück zum Zitat Cognetti F, Bruzzi P, De PS, De LM, Boni C, Aitini E et al. (2013) Epirubicin and cyclophosphamide followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide followed by T in node-positive early breast cancer patients. Final results of the gruppo Italiano mammella 2 randomized phase III study. Cancer Res 73(24):suppl 1. Cognetti F, Bruzzi P, De PS, De LM, Boni C, Aitini E et al. (2013) Epirubicin and cyclophosphamide followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide followed by T in node-positive early breast cancer patients. Final results of the gruppo Italiano mammella 2 randomized phase III study. Cancer Res 73(24):suppl 1.
64.
Zurück zum Zitat Richardet E, Richardet M, Brombin R, Cortes MN, Molina M, Riso AA et al. (2014) Concurrent chemoradiotherapy (CRT) with paclitaxel in breast cancer stage II-III. J Clin Oncol 32(15):Suppl 1. Richardet E, Richardet M, Brombin R, Cortes MN, Molina M, Riso AA et al. (2014) Concurrent chemoradiotherapy (CRT) with paclitaxel in breast cancer stage II-III. J Clin Oncol 32(15):Suppl 1.
65.
Zurück zum Zitat Eduardo arnoldo Richardet, Perelli Laura, Martin Eduardo Richardet, Nicolas Castagneris, Matias Nicolas Cortes MM. (2012) Concomitant chemoradiotherapy in women with stage II-III breast cancer. J Clin Oncol 30:suppl;abstr e11501. Eduardo arnoldo Richardet, Perelli Laura, Martin Eduardo Richardet, Nicolas Castagneris, Matias Nicolas Cortes MM. (2012) Concomitant chemoradiotherapy in women with stage II-III breast cancer. J Clin Oncol 30:suppl;abstr e11501.
66.
Zurück zum Zitat De La Haba-Rodríguez J, Rodríguez-Lescure A, Ruiz A, et al. (2011) Regional and seasonal influence in patient’s toxicity to adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat 125(1):273–278CrossRefPubMed De La Haba-Rodríguez J, Rodríguez-Lescure A, Ruiz A, et al. (2011) Regional and seasonal influence in patient’s toxicity to adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat 125(1):273–278CrossRefPubMed
67.
Zurück zum Zitat Palappallil DS, Nair BL, Jayakumar KL, et al. (2011) Comparative study of the toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycin-cyclophosphamide followed by paclitaxel in carcinoma breast. Indian J Cancer 48(1):68–73CrossRefPubMed Palappallil DS, Nair BL, Jayakumar KL, et al. (2011) Comparative study of the toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycin-cyclophosphamide followed by paclitaxel in carcinoma breast. Indian J Cancer 48(1):68–73CrossRefPubMed
68.
Zurück zum Zitat Esteva FJ, Franco SX, Hagan MK, et al. (2013) An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. Oncologist 18(6):661–666CrossRefPubMedPubMedCentral Esteva FJ, Franco SX, Hagan MK, et al. (2013) An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. Oncologist 18(6):661–666CrossRefPubMedPubMedCentral
69.
Zurück zum Zitat Moinpour C, Donaldson G, Liepa A, Albain K (2012) Evaluating health-related quality of life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monothe. Qual Life Res 21:765–775CrossRefPubMed Moinpour C, Donaldson G, Liepa A, Albain K (2012) Evaluating health-related quality of life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monothe. Qual Life Res 21:765–775CrossRefPubMed
70.
Zurück zum Zitat Lück H-J, Andreas Du Bois B, Sibylle Loibl B, Iris Schrader B, Jens Huober B, Volker Heilmann B, et al. (2013) Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO breast cancer study group. Breast Cancer Res Treat 139:779–787CrossRefPubMed Lück H-J, Andreas Du Bois B, Sibylle Loibl B, Iris Schrader B, Jens Huober B, Volker Heilmann B, et al. (2013) Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO breast cancer study group. Breast Cancer Res Treat 139:779–787CrossRefPubMed
71.
Zurück zum Zitat Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, et al. (2010) A randomized phase II trial comparing 3-h versus 96-h infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer 116 (4):814–821. Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, et al. (2010) A randomized phase II trial comparing 3-h versus 96-h infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer 116 (4):814–821.
72.
Zurück zum Zitat Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Kelly Marcom P, et al. (2007) Trastuzumab plus Vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and Vinorelbine or taxane study. Cancer 110(5):965–972CrossRefPubMed Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Kelly Marcom P, et al. (2007) Trastuzumab plus Vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and Vinorelbine or taxane study. Cancer 110(5):965–972CrossRefPubMed
73.
Zurück zum Zitat Talbot D, Moiseyenko V, Van BS, O ‘reilly S, Conejo EA, Ackland S, et al. (2002) Randomised, phase II trial comparing oral capecitabine (Xeloda 1) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86(9):1367–1372CrossRefPubMedPubMedCentral Talbot D, Moiseyenko V, Van BS, O ‘reilly S, Conejo EA, Ackland S, et al. (2002) Randomised, phase II trial comparing oral capecitabine (Xeloda 1) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86(9):1367–1372CrossRefPubMedPubMedCentral
74.
Zurück zum Zitat Jassem J, Pienkowski T (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707–1715PubMed Jassem J, Pienkowski T (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707–1715PubMed
75.
Zurück zum Zitat Saracchini S, Foltran L, Bassini A, Sulfaro S, Lorenzon M, Micheli E et al. (2014) Neoadjuvant chemotherapy with nonpegylated liposome-encapsulated doxorubicin (NPLD) plus cyclophosphamide followed by trastuzumab plus nabpaclitaxel for HER2-positive breast cancer (BC). J Clin Oncol 32(15):suppl 1 Saracchini S, Foltran L, Bassini A, Sulfaro S, Lorenzon M, Micheli E et al. (2014) Neoadjuvant chemotherapy with nonpegylated liposome-encapsulated doxorubicin (NPLD) plus cyclophosphamide followed by trastuzumab plus nabpaclitaxel for HER2-positive breast cancer (BC). J Clin Oncol 32(15):suppl 1
76.
Zurück zum Zitat Tsugawa K, Kawamoto H, Kojima Y, Tsuchiya K, Shimo A, Hayami R et al. (2014) Feasibility study of weekly nanoparticle albumin-bound (nab)-paclitaxel (150 mg/m2) followed by 5FU, epirubicin, plus cyclophosphamide (FEC) as neoadjuvant chemotherapy for HER2-negative breast cancer. Eur J Cancer 50(S51). Tsugawa K, Kawamoto H, Kojima Y, Tsuchiya K, Shimo A, Hayami R et al. (2014) Feasibility study of weekly nanoparticle albumin-bound (nab)-paclitaxel (150 mg/m2) followed by 5FU, epirubicin, plus cyclophosphamide (FEC) as neoadjuvant chemotherapy for HER2-negative breast cancer. Eur J Cancer 50(S51).
77.
Zurück zum Zitat Seki H, Asanuma F, Yamada Y, Hirata Y, Kaneda M, Suzuki K et al. (2014) Safety of weekly administration of nanoparticle albumin-bound paclitaxel in patients with breast cancer. Eur J Cancer 50(e.41). Seki H, Asanuma F, Yamada Y, Hirata Y, Kaneda M, Suzuki K et al. (2014) Safety of weekly administration of nanoparticle albumin-bound paclitaxel in patients with breast cancer. Eur J Cancer 50(e.41).
78.
Zurück zum Zitat Schwartzberg LS, Arena FP, Mintzer DM, Epperson AL, Walker MS (2012) Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer. Clinical Breast Cancer 12(2):87–93CrossRefPubMed Schwartzberg LS, Arena FP, Mintzer DM, Epperson AL, Walker MS (2012) Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer. Clinical Breast Cancer 12(2):87–93CrossRefPubMed
79.
Zurück zum Zitat Seidman AD, Conlin AK, Bach A, Moynahan ME, Lake D, Forero A, et al. (2013) Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer. Clinical Breast Cancer 13(4):239–46.e1. Seidman AD, Conlin AK, Bach A, Moynahan ME, Lake D, Forero A, et al. (2013) Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer. Clinical Breast Cancer 13(4):239–46.e1.
80.
Zurück zum Zitat Pasekta M, De Angelis C, Van Draanen J, Stacey E, Dent R (2011) Characterization of taxane-induced arthralgias and myalgias in breast cancer patients at two ambulatory cancer centres: a Prospecrtive observational study. Support Care Cancer 19(supp 2):s67–370 Pasekta M, De Angelis C, Van Draanen J, Stacey E, Dent R (2011) Characterization of taxane-induced arthralgias and myalgias in breast cancer patients at two ambulatory cancer centres: a Prospecrtive observational study. Support Care Cancer 19(supp 2):s67–370
81.
Zurück zum Zitat Fernandes R, Mazzarello S, Majeed H, Smith S, Shorr R, Hutton B, et al. (2016) Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review. Support Care Cancer 24(4):1583–1594 Fernandes R, Mazzarello S, Majeed H, Smith S, Shorr R, Hutton B, et al. (2016) Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review. Support Care Cancer 24(4):1583–1594
82.
Zurück zum Zitat Damaraju S, Ghosh S, Tuszynski J, Greiner R, et al. (2010) CYP3A5*3 (rs776746) is associated with docetaxel-specific toxicities during adjuvant breast cancer chemotherapy. Eur J Cancer 8(suppl 7):175CrossRef Damaraju S, Ghosh S, Tuszynski J, Greiner R, et al. (2010) CYP3A5*3 (rs776746) is associated with docetaxel-specific toxicities during adjuvant breast cancer chemotherapy. Eur J Cancer 8(suppl 7):175CrossRef
83.
Zurück zum Zitat Damaraju S, Sehrawat BS, Ghosh S, Pituskin E, et al. (2010) Germline Copy Number Polymorphisms Associated with Toxicity from Adjuvant Docetaxel. Cancer Res 70(suppl(24)):258s Damaraju S, Sehrawat BS, Ghosh S, Pituskin E, et al. (2010) Germline Copy Number Polymorphisms Associated with Toxicity from Adjuvant Docetaxel. Cancer Res 70(suppl(24)):258s
Metadaten
Titel
Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review
verfasst von
Ricardo Fernandes
Sasha Mazzarello
Brian Hutton
Risa Shorr
Habeeb Majeed
Mohammed FK Ibrahim
Carmel Jacobs
Michael Ong
Mark Clemons
Publikationsdatum
05.05.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3256-5

Weitere Artikel der Ausgabe 8/2016

Supportive Care in Cancer 8/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.